Related Experiment Videos
Clinical utility of angiotensin converting enzyme inhibitors in hypertension
Insights
Angiotensin converting enzyme (ACE) inhibitors effectively treat hypertension and heart failure by lowering blood pressure and improving cardiac function. These drugs offer significant benefits with minimal side effects, especially newer generations.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Nephrology
Background:
- Oral angiotensin converting enzyme (ACE) inhibitors have been available for eight years.
- These medications are increasingly utilized for managing hypertension and congestive heart failure.
- Their mechanism involves suppressing the renin-angiotensin-aldosterone system.
Purpose of the Study:
- To review the efficacy and safety of oral ACE inhibitors in treating hypertension and congestive heart failure.
- To highlight the benefits of ACE inhibitors, including blood pressure reduction and organ protection.
- To discuss the suitability of ACE inhibitors for specific patient populations and compare different drug generations.
Main Methods:
- Review of existing clinical data and therapeutic outcomes associated with oral ACE inhibitors.
- Analysis of physiological effects, including hemodynamic changes and hormonal suppression.
- Evaluation of response rates in monotherapy and combination therapy with diuretics.
Main Results:
- ACE inhibitors lower blood pressure, suppress angiotensin and aldosterone, and improve regional blood flow.
- Long-term benefits include decreased sympathetic drive and regression of left ventricular hypertrophy.
- Monotherapy is effective in over 50% of patients; adding a diuretic increases response rates to over 80%.
Conclusions:
- Oral ACE inhibitors are highly effective treatments for hypertension and congestive heart failure.
- They are well-tolerated, with side effects being rare, particularly with second-generation inhibitors.
- ACE inhibitors are a preferred treatment option for patients with comorbidities like diabetes and asthma.
Abstract:
Oral angiotensin converting enzyme inhibition was introduced eight years ago and is becoming increasingly popular for the treatment of hypertension and congestive heart failure. This treatment causes blood pressure lowering associated with suppression of angiotensin and aldosterone, lack of orthostatic hypotension or metabolic disturbances, redistribution of regional blood flows in favor of vital organs and, in the long term, decreased sympathetic drive and regression of left ventricular hypertrophy. It is effective as monotherapy in more than 50 percent of unselected patients; addition of a diuretic increases the percentage of responders to more than 80 percent. It is the treatment of choice for patients with concurrent diabetes, asthma, gout, depression, or very active life-style. Side effects, observed originally in patients with severe hypertension and renal failure treated with very high doses of captopril, are rare in otherwise healthy hypertensive patients receiving smaller doses of this drug and virtually absent with second-generation angiotensin converting enzyme inhibitors like enalapril.